MULTIMERIN2 (MMRN2), also known as Endoglyx-1, is an extracellular matrix glycoprotein whose function has so far remained elusive. Given its specific localization in tight association with the endothelium we hypothesized that this protein could modulate neo-angiogenesis. By multiple assays we showed that MMRN2 significantly impaired endothelial cell (EC) migration and organization of a functional vessel network. The interaction of ECs with MMRN2 induced a striking impairment of VEGFR1 and VEGFR2 activation. We focused our attention on VEGFR2, a chief regulator of angiogenesis, and clarified that MMRN2 interfered with the VEGF/VEGFR2 axis through a direct binding with VEGF-A. This novel interaction was assessed in several assays and the affinity was estimated (KdB50 nM). We next questioned whether the anti-angiogenic properties of MMRN2 could impair tumor growth. Although overexpression of MMRN2 by HT1080 cells did not affect their growth and apoptotic rate in vitro, it remarkably affected their growth in vivo. In fact, MMRN2-positive cells failed to efficiently grow and form well-vascularized tumors; a similar outcome was observed following treatment of established tumors with a MMRN2 adenoviral construct. Tumor-section immunostaining revealed a strong co-localization of VEGF-A with the ectopically expressed MMRN2. These novel findings suggest that VEGF may be sequestered by MMRN2 and be less available for the engagement to the receptors. Taken together these results highlight MMRN2 as a crucial player in the regulation of EC function, neoangiogenesis and hence tumor growth. We hypothesize that secreted and deposited MMRN2 may function as a homeostatic barrier halting the sprouting of novel vessels, and suggest that these studies may embody the potential for the development of novel tools for cancer treatment.
Introduction
The development of new blood vessels is of vital importance for normal growth and development, as well as for pathological conditions such as tumor development. Solid tumors do not grow beyond the size of 1-2 mm unless the homeostatic balance between proand anti-angiogenic molecules is altered, and the formation of new blood vessels is induced. The newly formed vessels provide the oxygen and the nutrients necessary for the relentless growth and expansion of the tumor, and favor invasion and metastasis (Folkman, 1971) . In the latest years it has become clear that the different cellular and acellular components of the tumor microenvironment are pivotal regulators of tumor development (Hu and Polyak, 2008; Joyce and Pollard, 2009) . Indeed, the tumor represents a functional tissue interconnected with the microenvironment. The cellular components are surrounded by and intermingled with a complex network of extracellular matrix (ECM) molecules that sustain and favor communication between the cells and the external milieu. One key role of the ECM that has gained prominent recognition is the regulation of tumor angiogenesis (Cheresh and Stupack, 2008; Nyberg et al., 2008) . During blood vessel sprouts, endothelial cells (ECs) must not only coordinate cytoskeletal changes to move through the tissues but also secrete proteolytic enzymes to promote matrix degradation that favors invasion and affect angiogenesis (Carmeliet, 2000; Nyberg et al., 2008; Campbell et al., 2010) . Several ECM molecules or degradation products have been reported to negatively (Boehm et al., 1997; Lawler, 2002; Mongiat et al., 2003) or positively (Hirama et al., 2003; Mongiat et al., 2010; Ventura et al., 2010) 
affect angiogenesis.
VEGF-A is expressed by most types of tumors (Ferrara, 2002) , and is a regulator of vascular development that binds VEGFR1 and VEGFR2 receptor tyrosine kinases (RTKs) expressed on the EC membrane (Mustonen and Alitalo, 1995; Olsson et al., 2006) . VEGFR1 is important for the recruitment of hematopoietic precursors and migration of monocytes and macrophages, and VEGFR2 is required for EC function and accounts for most of the VEGF-A-mediated downstream signaling occurring during angiogenesis. In particular, tyrosine 1175 (Tyr 1175 ) and tyrosine 951 (Tyr 951 ) phosphorylation have been shown to be primarily implicated in the regulation of EC migration (Olsson et al., 2006) . VEGF-A binds to a number of ECM molecules (Kupprion et al., 1998; Gengrinovitch et al., 1999; Sahni and Francis, 2000; Wijelath et al., 2002; Greenaway et al., 2007; Zoeller et al., 2009) and ECM-bound VEGF-A either prolongs (Hutchings et al., 2003; Chen et al., 2010) or impairs VEGFR2 activation (Kupprion et al., 1998; Sun et al., 2009) , thus affecting EC proliferation to a great extent.
MULTIMERIN2 (MMRN2), also known as EndoGlyx-1, is an ECM member of the EDEN (EMI Domain ENdowed) protein family (Braghetta et al., 2004) associated with a high molecular weight glycoprotein complex (Christian et al., 2001) . The molecule displays a panendothelial expression pattern both in normal and tumoral vasculature, including hot spots of neovascularization in some tumors (Sanz-Moncasi et al., 1994; Christian et al., 2001; Huber et al., 2006; Koperek et al., 2007) . It is specifically deposited along the blood vessels in tight juxtaposition with ECs and is also present in the luminal side of the vessels (Christian et al., 2001) , however, its function has thus far remained obscure. Here, we show evidence that MMRN2 contributes to the maintenance of blood vessels' homeostasis, and that its overexpression affects EC migration and tumor angiogenesis. MMRN2 interferes with the VEGF-A/VEGFR2 axis by VEGF-A sequestration, thus leading to a striking decrease of tumor growth.
Results
The adhesion of ECs to MMRN2 did not affect their viability or their apoptotic rate Given that MMRN2 is specifically deposited only in the blood vessels we wondered whether this molecule was secreted exclusively by ECs or also by smooth muscle cells. Western blot analysis performed on human umbelical vein endothelial cells (HUVEC) and pulmonary smooth muscle cells indicated that MMRN2 is produced only by ECs (Supplementary Figure 1a, top) . In addition, among several MMRN2-negative tumor cell lines (not shown), no MMRN2 expression was detected in the sarcoma (HT1080) and carcinoma (HeLa) tumor cell lines. In order to analyze its putative effects on ECs behavior we have either used purified recombinant MMRN2 (Figure 1a , left) or induced its overexpression in ECs through adenoviral transduction (Figure 1a , bottom, Supplementary Figure 1a , bottom). As previously demonstrated (Christian et al., 2001) , the purified recombinant molecule barely entered a 4-12% polyacrylamide gel under non-reducing conditions (Figure 1a , right). Alternatively, endogenous expression was downregulated by specific siRNA sequences, construct 4 giving the highest downregulation, which was optimal at 72 h post transduction (Supplementary Figure 1b and Figure 2d ). In accordance with the fact that MMRN2 is located in tight contact with the endothelium (Christian et al., 2001) , ECs adhered to MMRN2 even though the interaction was weaker compared with the adhesion to type I collagen, and was Ca 2 þ and Mg 2 þ independent (Figures 1b and c) . Furthermore, EC adhesion on MMRN2 was not affected by a number of anti-integrin blocking antibodies, including anti-a 1 , anti-a 4 , anti-a v and anti-b 1 (data not shown). MMRN2 did not affect the regular EC proliferation or their apoptotic rate (Figures 1d-g ). Similarly the downregulation of endogenous MMRN2 by RNA interference did not change the percentage of cells undergoing apoptosis nor their proliferative potential, a further indication that this molecule does not alter the normal EC growth (Supplementary Figure 1c) . Figure 1 MMRN2 is a substrate for ECs and does not alter their viability or the apoptotic rate. Left panel: SDS-PAGE analysis of two fractions of recombinant His-tagged MMRN2 (rMMRN2) or media from mock-transfected cells (mock). Right panel: Western blot analysis of the conditioned media from HUVEC cells transduced with the MMRN2 adenoviral construct and cultured with or without doxycycline (DOX þ and DOXÀ, respectively). Actin was used as a normalizer of protein loading (a). Adhesion assay (CAFCA, see Materials and methods) performed with HUVEC cells adhered on type I collagen (Coll I), MMRN2 or BSA using two centrifugal forces (spin of 46 or 12 g) (b). Adhesion assay in the absence of Ca 2 þ and Mg 2 þ (*P ¼ 0.003) (c). MTT assay performed on HUVEC cells treated with increasing concentrations of Coll I or MMRN2 (d) . MTT assay performed on HUVEC cells transduced with the MMRN2 adenoviral construct and cultured with or without doxycycline (DOX þ and DOXÀ, respectively) (e). TUNEL assay performed on HUVEC cells treated with 10 mg/ml of Coll I or MMRN2 (f). TUNEL assay performed on HUVEC cells transduced with the MMRN2 adenoviral construct and cultured with or without doxycycline (DOX þ and DOX-, respectively) (g).
MMRN2 significantly reduced EC motility and inhibited tubule sprouting
The ECs' migration towards a VEGF-A stimulus was significantly impaired by MMRN2 (Figure 2a ) and, differently from type I collagen, the molecule did not promote haptotactic migration of ECs (Figure 2b ). These results were also corroborated by the scratch test analysis, wherein ECs treated with MMRN2 failed to efficiently close the wound (Figure 2c and Supplementary  Figure 1d) . Accordingly, the downregulation of endogenous MMRN2 led to an increased migration of ECs towards the VEGF-A stimulus (Figures 2d and e) . Finally, MMRN2 significantly inhibited tubulogenesis induced by Matrigel (Figure 2f and Supplementary Figures 1e-g ). MMRN2 impaired VEGF-A-induced angiogenesis in vivo and VEGFR2 activation by sequestering VEGF-A We next verified the capability of MMRN2 to affect angiogenesis in a fibroblast/EC co-culture system and found that MMRN2 consistently impaired the formation of microvessels in a dose-dependent manner ( Figure 3a) . The putative anti-angiogenic activity was subsequently tested in vivo. The 'spoke-wheel-like' blood vessel development toward the sponge containing VEGF-A in chorioallantoic membrane (CAM) assays was significantly impaired in the presence of MMRN2 (P ¼ 0.01, Figures 3b and c) . On the contrary, the decreased blood vessel formation toward a basic fibroblast growth factor (bFGF) stimulus was not significant, suggesting that the effect might specifically involve VEGF-A signaling; moreover, MMRN2 per se did not significantly affect angiogenesis in this assay ( Representative pictures of CAM assays performed using sponges (white asterisk) containing 50 ng of VEGF-A or bFGF with or without 150 ng of MMRN2. Phosphate-buffered saline or MMRN2 without stimulus were used as a control (b). Quantification of the newly formed vessels directed toward the sponge by following or not the stimulus with VEGF-A or bFGF (V and F, respectively) of the experiment above. Twenty eggs were used for each point and the values represent mean ± s.e. of three independent experiments (*P ¼ 0.01) (c). Representative pictures of the aortic ring assay. Aortas were challenged with phosphate-buffered saline (CNTRL) or 10 mg/ml of MMRN2 (d). Evaluation of the number of vessels sprouting from the aortas. Four aortas per group were used (*Pp0.002) (e).
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of cold VEGF-A or MMRN2 were performed. MMRN2 induced a considerable displacement of radiolabelled VEGF-A, indicating that this molecule interfered with the VEGF-A-VEGFR binding ( Figure 4d ). To verify if this effect did not require other molecules present on the EC surface we have performed a similar experiment using the recombinant extracellular domain of VEGFR2. In this case the displacement was even stronger, comparable to that obtained with VEGF-A; on the contrary, type I collagen did not displace VEGF-A from its receptor (Figure 4e ). The specificity of MMRN2 in interfering with the VEGF-A/VEGFR2 interaction was corroborated in ELISA tests following coating of plates with recombinant VEGFR2, incubation with soluble VEGF-A and challenging with type I collagen or MMRN2 (Supplementary Figure 2c) . Next, through an ELISA test using soluble VEGF-A and immobilized MMRN2, we confirmed that MMRN2 directly interacted with VEGF-A (Figure 4f ). The strength of the MMRN2/ VEGF-A interaction was further confirmed by surface plasmon resonance analysis (KdB50 nM; Figure 4g and Supplementary Figure 2d) . 
MMRN2 negatively affected tumor angiogenesis and growth
To verify whether MMRN2 could affect tumor angiogenesis and tumor growth in vivo we injected stably transfected HT1080 cells in nude mice. Two stable clones were chosen with slightly different expression levels (Supplementary Figure 3a) . Strikingly, the ectopic secretion of MMRN2 led to an almost complete blockage of tumor growth (Figures 5a and b and Supplementary Figures 3b and c) . The anti-tumor effect of MMRN2 was even more prominent when using the high-expressing clone 4, the mean of the tumor volumes obtained with clone 9 being more than threefold those obtained with clone 4. The MMRN2 effect was so strong that with this approach only two tumors could be excised for further analysis. The ectopic expression of MMRN2 by HT1080 cells, which do not normally express this molecule, did not alter their viability or their apoptotic rate, indicating that MMRN2 did not affect tumor cell behavior (Figures 5c and d) . The effect had thus to be indirect and, given our compelling evidences establishing a negative role of MMRN2 in the regulation of angiogenesis, we verified whether the lack of tumor growth was because of reduced intra-tumor angiogenesis. Compared with the controls, the vascular density and overall length of the vessels were significantly lower in the MMRN2-transfected cell tumors (Figures 5e and f) . Moreover, the vessels from the MMRN2-positive tumors were less mature and thus likely less efficient in providing oxygen and nutrients to the growing tumors (Figures 5g and h) . Accordingly, and unlike the controls, the tumors derived from MMRN2-transfected cells displayed extended hypoxic regions, despite their size, which was much smaller (Figure 6a and Supplementary Figure 3d) . To corroborate the limited data obtained with the use of HT1080-transfected cells, where only two tumors were available for the analysis, and to verify whether MMRN2 could be effective also on established tumors, we treated growing tumors with the MMRN2 adenoviral construct. Also with this approach, the reduction of tumor growth was consistent, even though less striking compared with that observed with the use of the MMRN2 stably transfected cells (Figure 6b ). In this case we could recover all the tumors for further analysis which suggested that, despite the fact that the vessels' length was similarly reduced, the partial effect could likely depend on a less efficient reduction of the blood vessel density compared with that obtained with the transfected cells (Figures 6c and d) . The expression of VEGF-A by the tumors from mock and MMRN2-transfected HT1080 cells was confirmed by RT-PCR and western blot on tumor cell lysates, and by immunofluorescence on frozen sections (Supplementary  Figures 3e, f and g ). Next, we demonstrated that the Gv39M antibody specifically recognizing the VEGFR2-bound VEGF-A also detected the MMRN2-bound VEGF-A (Supplementary Figure 3h) . The Gv39M antibody revealed a diffuse staining in the MMRN2-overexpressing tumors, also in areas distant from the CD31-positive blood vessels (Figures 6e and f) . Here the staining mainly co-localized with recombinant MMRN2 produced by the transfected HT1080 cells (Supplementary Figure 3i ), again suggesting that MMRN2 may function by sequestering VEGF-A and preventing VEGF-A/VEGFR2 interaction.
Discussion
Despite its discovery dates to the nineties, before this study the function of MMRN2 has been fully obscure. Our investigation was driven by the hypothesis that its specific localization along the blood vessels and the intimate contact with ECs (Christian et al., 2001 ) could affect their behavior and hence play an important role in the regulation of angiogenesis.
Here we provided evidence that MMRN2 was secreted by ECs and did not affect their proliferation or their apoptotic rate, whereas it significantly impaired their motility. The MMRN2-dependent inhibition of EC motility was not likely mediated by integrins because adhesion of EC was independent of Mg 2 þ and Ca 2 þ , and was unaffected by integrin-blocking antibodies. The development of new blood vessels was negatively affected by MMRN2 in all the tests that we have carried out both in vitro, including tubule formation and co-culture systems, as well as in in/ex vivo CAM and aortic ring assays. The negative effect of MMRN2 in regulating angiogenesis may likely depend on the endogenous VEGF-A released by ECs when not added directly in the various tests (Roccaro et al., 2006) , for instance the sprouting of novel vessels in aortic ring assays is highly dependent on endogenously released VEGF-A (Ligresti et al., 2011) . Although the inhibition of EC motility was directly linked to MMRN2, it cannot be excluded that the striking effects in halting angiogenesis in vivo may also depend on its influence on other cell types that may be responsible for an amplification of the anti-angiogenic effects of this molecule (Anghelina et al., 2006; Nicosia, 2009) .
The interaction of MMRN2 with ECs led to the downregulation of two RTKs present on the ECs' surface, VEGFR1 and VEGFR2. VEGFR2 accounts for most of the VEGF-A effects on adult ECs (Waltenberger et al., 1994) and its phosphorylation in presence of MMRN2 was significantly impaired. The reduced phosphorylation of Tyr 1175 , which is known to be implicated in the regulation of EC migration (Holmqvist et al., 2004) , and the impaired phosphorylation of FAK were both in agreement with the biological findings. The inhibition of this pathway by MMRN2 was likely dependent on the interference with the VEGF-A/VEGFR2 axis, as demonstrated by the significant displacement of 125 I-VEGF-A from the EC surface and from recombinant VEGFR2. The incomplete displacement of the EC-bound VEGF-A, in addition to its interaction with heparin sulfate proteoglycans, was probably also the consequence of a lower affinity of this interaction (B50 nM), compared with that of VEGFR1 (B10-20 pM) (de Vries et al., 1992) and of 
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E Lorenzon et al VEGFR2 (B75-125 pM) (Terman et al., 1992) for VEGF-A. The interference of MMRN2 with the VEGF-A/VEFGR interaction was because of a direct binding of VEGF-A to MMRN2, as indicated by both ELISA and surface plasmon resonance analysis. It is reasonable to assume that MMRN2, because of its deposition and localization in tight contact with ECs, may attain a high pericellular concentration and thus represent an important competitor for the binding of VEGF-A to VEGFR2. This hypothesis, also in view of the relatively low density of this receptor on the cell surface (B10 000-25 000 molecules/cell) (Hotz et al., 2010) , is very likely. The reason why MMRN2 impaired only EC motility remains at the moment elusive, but may depend on a simultaneous activation of other pathways mainly affecting cell proliferation. This hypothesis is supported by the fact that, unlike FAK, Erk 1/2 phosphorylation does not vary in the presence of MMRN2 (data not shown). This effect is unique for MMRN2, as most ECM molecules that bind VEGF-A MULTIMERIN2 impairs tumor angiogenesis and growth E Lorenzon et al also affect cell proliferation (Kupprion et al., 1998; Sahni and Francis, 2000) .
Our biological results and the elucidation of the molecular mechanisms responsible for the MMRN2 anti-angiogenic activity were consistent with the outcome of the tumor growth studies. The MMRN2-transfected cells were per se not affected in their apoptotic nor proliferation rate by the ectopic expression of the molecule, but they almost failed to develop tumors when injected into nude mice. The finding that the MMRN2-positive tumors displayed a significantly lower vascular density suggested that the anti-tumor effects could likely be due to indirect effects hinging on a reduced blood supply, and a consequent depletion of oxygen and nutrients indispensable for tumor growth. The result was similar in tumors treated with MMRN2 adenoviral particles. Here, despite the limitations inherent to the inefficient and incomplete transduction of the tumor cells in vivo and the low number of injections performed, a less pronounced reduction of the blood vessel density was obtained as opposed to the higher reduction observed with the use of stably transfected cells. This represented a further indication of an indirect, angiogenic-dependent anti-tumoral role of MMRN2. The effect on vascular density was further exacerbated by the fact that tumor vessels from MMRN2 overexpressing tumors were less mature and thus less efficient, suggesting that MMRN2 may also affect pericyte recruitment. The use of the Gv39M antibody recognizing only the VEGFR2-bound VEGF-A granted further support to our hypothesis of an interference of MMRN2 with the VEGF-A/VEGFR2 axis; VEGF-A co-localized with MMRN2 produced by the transfected HT1080 cells in vivo, corroborating the results obtained through the ELISA tests, which indicated that the antibody also recognized the MMRN2-bound VEGF-A. This latter result indicated that the sequestration of VEGF-A by MMRN2 may prevent the interaction with VEGFR2 leading to a decreased intra-tumoral angiogenesis and consequent impaired tumor growth. Interestingly, database analysis for MMRN2 (www.oncomine.org) indicates that this molecule is differentially expressed in many types of tumors such as brain, breast, kidney and sarcomas if compared with the normal counterpart. Many of these tumors are highly angiogenesis dependent and it is conceivable that the dysregulation of MMRN2 expression might have an impact on tumor progression affecting the intra-tumoral vascularization.
In conclusion, with this study we provided evidence that MMRN2 may represent a novel key homeostatic molecule indispensable for the maintenance of blood vessel integrity. These findings were coherent with the hypothesis that MMRN2 may function as a 'biological barrier' keeping ECs in a steady-state condition and that the downregulation of endogenous MMRN2 or even the possible degradation by yet unidentified specific protease(s) could determine efficient sprouting and differentiation of ECs to form novel blood vessels. Our results provide further evidence of the intricate interplay of ECM molecules and cells within the tumor microenvironment, and open the possibility for the development of new anti-angiogenic drugs useful for cancer treatment.
Materials and methods

Cell lines
Human embryonic kidney cells (HEK 293, ATCC CRL-1573, Milan, Italy) were grown in Dulbecco's modified Eagle medium (Cambrex Bio Science, Milan, Italy) containing 10% fetal bovine serum and 1% penicillin-streptomycin. 293-EBNA (Epstein-Barr Nuclear Antigen) cells were a gift from Rupert Timpl. The HT1080 and HeLa cell lines were from ATCC, and cultured in Dulbecco's modified Eagle medium containing 10% fetal bovine serum. Pulmonary artery smooth muscle cells (PASMC) were from Lonza Ltd (Visp, Switzerland) and cultured in the provided medium. HUVEC cells were isolated from human umbilical cord veins as previously described (Jaffe et al., 1973) . Cells were cultured in Medium 199 (GIBCO, Invitrogen, Milan, Italy) supplemented with 20% fetal bovine serum, 1% penicillin-streptomycin, 50 mg/ml heparin and bovine brain extract (0.5%).
Antibodies and other reagents
The anti-MMRN2 polyclonal antibody was obtained upon immunization of a rabbit with 150 mg of a recombinant MMRN2 fragment corresponding to the N-terminal gC1q domain preceded by the proline-rich domain. The NaeI and XhoI restriction fragment from the full-length pcDNA construct (see below) was sub-cloned into the pQE-30 vector, expressed in bacteria and purified by means of the Ni-NTA resin, and exclusively used for immunization purposes in the present work. The antibody was affinity purified from the rabbit serum by means of the CNBr-activated Sepharose 4B resin (Amersham, GE-Healthcare, Milan, Italy). The anti-FLAG and a-SMA antibodies, the FLAG peptide, and the anti-FLAG M2 affinity gel were from Sigma-Aldrich (Milan, Italy). The secondary horse radish peroxidase-conjugated antibodies were from Amersham. The secondary antibodies conjugated with Alexa Fluor 680 were from Invitrogen. The Ni-NTA agarose was from QIAGEN (Milan, Italy). BD Adeno-X Rapid Titer Kit was from BD Biosciences (Milan, Italy). The AngioKit was from TCS CellWorks (Buckingham, UK). The anti-mouse anti-CD31 antibody and Matrigel were from BD Biosciences. Anti-VEGFR2 and anti phospho-VEGFR2 (Tyr 
Recombinant adenovirus
For MMRN2 overexpression, tetracycline-inducible recombinant adenoviruses were constructed according to the manufacturer's instructions using the Adeno-X Tet-On Expression System 2 (Clontech Laboratories, Milan Italy). HUVEC cells were co-transduced with a regulatory virus Adeno-X Tet-On and the MMRN2 recombinant virus at a specific multiplicity of infection ratio (800:320). Doxycyline was employed at a final concentration of 0.5 mg/ml. For the endogenous MMRN2 downregulation, the Knockout RNAi System was used (Clontech). The targeted sequences were: siRNA 1: 5 0 -GAGGAACCTCTCAGAGCTGCACAT GACCA-3 0 ; siRNA 2: 5 0 -GGATGAGATCAAGGAACTGT ACTCCGAAT-3 0 ; siRNA 3: 5 0 -CCTCATCAAGTACGTGA AGGACTGCAATT-3 0 ; siRNA 4: 5 0 -GCAGACAGTGAAG TTCAACACCACATACA-3 0 .
Western blotting analysis and immunohistochemistry Cells were lysed in cold HNTG buffer (1% Triton X-100, 20 mM HEPES pH 7.5, 10% glycerol, 150mM NaCl) containing a protease inhibitors cocktail (Roche Diagnaostics S.p.a., Milan, Italy) and 1 mM sodium orthovanadate. Proteins were resolved in 4-20% Criterion Precast Gels (Bio-Rad Laboratories, S.r.l., Milan, Italy) and transferred onto Hybond-ECL nitrocellulose membranes (GE-Healthcare). The blots were developed using ECL (GE-Healthcare) and exposed to X-ray films. Alternatively the Odyssey infrared imaging system was used (Li-COR Biosciences, Lincoln, NE, USA). For immunohistochemistry, tumors were included in optimal cutting temperature compound (OCT) and frozen. Sections of 7 mm thickness were made and stained with anti-mouse CD31 and/or a-SMA antibodies. Images were acquired with a Leica TCS SP2 confocal system (Leica Microsystems GmbH, Milan, Italy). Alternatively five mice injected in both flanks as above were treated with 60 mg/kg of pimonidazole HCl 45 min prior being killed and sections were stained with the PAb2627 (hypoxyprobe-1, CHEMICON, Temacula, CA, USA) according to the manufacturer instructions.
Radioligand displacement studies, ELISA and Surface Plasmon Resonance analysis. For the displacement of HUVEC-bound 125 I-VEGF-A (Perkin Elmer, Milan, Italy), 2 Â 10 5 HUVEC cells were used per point. Cells were incubated with 70 pM 125 I-VEGF-A and increasing concentrations of cold-VEGF-A or recombinant full-length MMRN2, incubated on ice for 1 h, collected, and counts obtained with the Wizard 2 GAMMA Counter (Perkin Elmer). In alternative, the recombinant VEGFR2 Fc chimera (R&D Systems, Inc., Milan, Italy) was used and coated on ELISA plates (10 ng/well). Bound 125 I-VEGF-A was rescued using 2 M NaOH at 50 1C and type I collagen was used as a control. For the ELISA tests, 0.5 mg of MMRN2 or bovine serum albumin (BSA) were coated, blocked with 2% BSA and incubated with soluble VEGF-A (100 ng/well) for 1 h at 37 1C. Binding was verified with the anti-VEGF-A antibody; the ABTS substrate was added and absorbance at 405 nm detected with a spectrophotometer (TECAN, Milan, Italy) . For BIAcore analysis MMRN2 was immobilized onto CM5-dextran matrix chip from BIAcore Life Sciences (GE Healthcare) using amine coupling to a density of 2160 resonance units (RU); 37 ng/ml of MMRN2 in acetate pH ¼ 4 was used. Different concentrations of VEGF 165 were injected as analyte and the kinetics of the interaction detected by means of the BIAcore X-100 instrument.
MTT and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays Following over-or downregulation of MMRN2 expression or treatment with the recombinant protein, 0.3 mg/ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent was added and cells were incubated at 37 1C for 4 h. Absorbance at 560 nm was detected following solubilization of crystals with dimethyl sulfoxide. The apoptotic rate was determined using the ApopTag Fluorescein in situ Oligo Ligation Apoptosis Detection Kit (CHEMICON International).
RTK array RTK activation was evaluated using the Human Phospho-RTK Array Kit (R&D Systems). HUVEC cells were incubated for 30 min with the conditioned media from HUVEC cells transduced with the MMRN2 or control adenoviral vectors (collected 72 h post transduction), the experiment was performed according to the manufacturer's instructions and spots' intensity was evaluated with the Image Tool software (University of Texas Health Science Center, San Antonio, TX, USA).
Cell adhesion, migration, haptotaxis, scratch test and tube formation assays Centrifugal Assay for Fluorescence-based Cell Adhesion was performed as previously described (Spessotto et al., 2000) . The miniplates were coated with 10 mg/ml full-length MMRN2 or type I collagen and saturated with 1% denatured BSA. The units were centrifuged upside down for 5 min at 12 or 46 g and the fluorescence was measured using the GENios Plus instrument (TECAN). Fluorescence-Assisted Transmigration Invasion and Motility Assay was performed as previously described (Spessotto et al., 2000) . The transwell membranes were coated with 10 mg/ml of MMRN2 or type I collagen and blocked with 1% BSA. Cells were labeled with DiI (Molecular Probes, Invitrogen) and were let to migrate toward a VEGF-A stimulus (50 ng/ml). Migration was monitored using the computer-interfaced GENios Plus instrument. In alternative, migrated cells were estimated by counting following hematoxylin and eosin staining. Haptotaxis was assessed by plating the molecules on the underside of the membranes. For scratch test analysis, confluent cells were starved overnight and a scratch wound was made using a sterile pipette tip. Cells were washed and incubated with medium containing 0.5% serum in the presence of 10 mg/ml of MMRN2 or type I collagen. Time course analysis was carried out by means of the LEICA AF6000 Imaging System (LEICA, Wetzlar, Germany).
Matrigel tube formation assays were performed as previously described (Mongiat et al., 2003) . HUVEC cells were resuspended in medium containing 0.5% serum and 10 mg/ml of purified full-length MMRN2 or type I collagen. When using the TCS CellWorks AngioKit, co-cultures were treated for 11 days with MMRN2 or phosphate-buffered saline. Cells were fixed and stained using the anti-CD31 antibody and the DAB substrate was provided. Vessel density was calculated by means of the Image Tool software.
CAM and aortic ring assays CAM assays were performed as previously described (Mongiat et al., 2003) . Fifty nanograms of VEGF-A or bFGF with or without 150 ng of MMRN2 was allowed to be absorbed by the sponges (Gelfoam, Upjohn Company, Kalamazoo, MI, USA). Phosphate-buffered saline or full-length MMRN2 only was used as a control. Twenty eggs each were used. After 4 days the CAMs were fixed and pictures were taken at the Stereo Microscope (Leica Microsystems GmbH). The vessels directed toward the sponge were evaluated by counting.
The aortic ring assays were performed as previously described (Aplin et al., 2008) . Rat thoracic aortas were dissected and cultured with or without 10 mg/ml of full-length MMRN2. Angiogenesis was measured by counting the number of neovessels over time.
In vivo tumor growth experiments Ten female athymic nude mice (Harlan S.r.l, Milan, Italy) were subcutaneously injected with 1 Â 10 6 HT1080 cells stably transfected with the MMRN2 pcDNA3.1 vector (right flanks) or the empty vector (left flanks). Two MMRN2 clones were used (clone 4 and 9) for a total number of 20 mice. Tumor growth was monitored, and after 19 days the animals were killed and tumors excised. Only two small MMRN2 overexpressing tumors grew and were available for immunohistochemical analysis. Alternatively, 1 Â 10 6 HT1080 cells were subcutaneously injected into 10 female athymic nude mice and let grow to a volume of 40-60 mm 3 . Tumors were then injected with 2 Â 10 9 total ifu (AdMMRN2/AdTet-ON, ratio 400:160) three times (dox-adenoviral construct). Three days before the first viral injection 1 mg/ml of doxycycline and 2.5% of sucrose was added to the drinking water of 5 out of 10 animals. Tumor size was measured with a caliper and the volume calculated with the following formula: (p Â length Â width 2 )/6.
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